Sep 2024 $60 M No. 7 $50 to $250 million 35
ONL Therapeutics, Inc.: Raise no. 7, Sep 2024 × Investors in this round 35 investors had bought by the notice of Sep 16, 2024: 35 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $60 M of $65 M offered; $5 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Constance Chang · Executive Officer David Esposito · Executive Officer, Director David Zacks · Executive Officer Aaron Fletcher · Director Bill Burns · Director Marian Nakada · Director Michal Silverberg · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by David Esposito, CEO & President. Source: SEC Form D, newest notice filed Sep 16, 2024. Read the notice at the SEC .
equity SEC Feb 2024 $10 M No. 6 $10 to $50 million 35
ONL Therapeutics, Inc.: Raise no. 6, Feb 2024 × Investors in this round 35 investors had bought by the notice of Mar 12, 2024: 35 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Constance Chang · Executive Officer David Esposito · Executive Officer, Director David Zacks · Executive Officer, Director Bill Burns · Director Mark Hooper · Director Stella Robertson · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by David Esposito, CEO & President. Source: SEC Form D, newest notice filed Mar 12, 2024. Read the notice at the SEC .
equity SEC Mar 2023 $5 M No. 5 $2 to $10 million 30
ONL Therapeutics, Inc.: Raise no. 5, Mar 2023 × Investors in this round 30 investors had bought by the notice of Mar 15, 2023: 30 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $15 M offered; $10 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Constance Chang · Executive Officer David Esposito · Executive Officer, Director David Zacks · Executive Officer, Director Bill Burns · Director Mark Hooper · Director Stella Robertson · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by David Esposito, CEO & President. Source: SEC Form D, newest notice filed Mar 15, 2023. Read the notice at the SEC .
equity SEC Dec 2020 $27 M No. 4 $10 to $50 million 44
ONL Therapeutics, Inc.: Raise no. 4, Dec 2020 × Investors in this round 44 investors had bought by the notice of Dec 30, 2020: 44 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $27 M of $47 M offered; $21 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Esposito · Executive Officer, Director David Zacks · Executive Officer, Director Bill Burns · Director Mark Hooper · Director Stella Robertson · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by David Esposito, CEO & President. Source: SEC Form D, newest notice filed Dec 30, 2020. Read the notice at the SEC .
equity SEC Oct 2020 $2 M No. 3 $2 to $10 million 3
ONL Therapeutics, Inc.: Raise no. 3, Oct 2020 × Investors in this round 3 investors had bought by the notice of Oct 30, 2020: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Esposito · Executive Officer, Director David Zacks · Executive Officer, Director Christine Gibbons · Director Felicia David-Visser · Director Mark Hooper · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by David Esposito, CEO & President. Source: SEC Form D, newest notice filed Oct 30, 2020. Read the notice at the SEC .
options SEC Aug 2019 $3 M No. 2 $2 to $10 million 25
ONL Therapeutics, Inc.: Raise no. 2, Aug 2019 × Investors in this round 25 investors had bought by the notice of Aug 22, 2019: 25 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Esposito · Executive Officer, Director David Zacks · Executive Officer, Director Christine Gibbons · Director Felicia David-Visser · Director Mark Hooper · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by David Esposito, CEO & President. Source: SEC Form D, newest notice filed Aug 22, 2019. Read the notice at the SEC .
debt, options SEC May 2017 $3 M No. 1 $2 to $10 million 19
ONL Therapeutics, Inc.: Raise no. 1, May 2017 × Investors in this round 19 investors had bought by the notice of May 19, 2017: 19 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $4 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Zacks · Executive Officer, Director John Freshley · Executive Officer, Director Christine Gibbons · Director Mark Hooper · Director Rafael Castilla · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by John K. Freshley, President and CEO. Source: SEC Form D, newest notice filed May 19, 2017. Read the notice at the SEC .
equity SEC